Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 210 (planned)
- Started
- Aug 7, 2024
- Main results expected
- May 9, 2028
- Fully finished
- Aug 8, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
Measured over: Up to ~28 days
Percentage of Particiapants who Experience an Adverse Event (AE) During the Safety Lead-In Phase
Measured over: Up to ~60 days
Percentage of Participants who Discontinue Study Intervention Due to an AE During the Safety Lead-In Phase
Measured over: Up to ~28 days
Objective Response Rate (ORR)
Measured over: Up to ~28 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06445972 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC